<DOC>
	<DOCNO>NCT03084562</DOCNO>
	<brief_summary>Myocardial perfusion scintigraphy evaluate coronary perfusion well heart muscle function . This examination take place two stage , one imaging rest one cardiac stress cause . This stress trigger first-line stress test . A pharmacological stress propose stress test possible contraindicate , Several drug market authorization indication ( adenosine , dipyridamole , regadenoson , dobutamine ) . Among , regadenoson recent molecule . Marketed France since 2013 , would allow reduction undesirable effect compare agent , especially adenosine . It simple quick use thanks single dose administration . However , cost nearly 30 time high dipyridamole . In investigational center , dipyridamole currently first-line pharmacological stress agent , whereas regadenoson reserve limited number dos , indication must justify ( asthmatic patient severe COPD ) . Few study literature specifically compare two pharmacological agent ( examination time , cost , tolerance ) opinion use regadenoson service limit .</brief_summary>
	<brief_title>Regadenoson v Dipyridamole Use Pharmacological Stress Agent Before SPECT</brief_title>
	<detailed_description />
	<mesh_term>Regadenoson</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>Adult â‰¥ 18 year Myocardial scintigraphy pharmacological stress agent Used molecule = Dipyridamole Regadenoson Physical stress test single mixed effort ( associate pharmacological stress ) Pharmacological agent use = Adenosine Inclusion ERCAD protocol Double isotope protocol Patient refusal due study information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>